<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185130</url>
  </required_header>
  <id_info>
    <org_study_id>2017-54</org_study_id>
    <nct_id>NCT03185130</nct_id>
  </id_info>
  <brief_title>Intravenous Fluids in Benign Headaches Trail</brief_title>
  <acronym>I-FiBH</acronym>
  <official_title>Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center of Southern Nevada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center of Southern Nevada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine headache has a 1-year period prevalence in the US of 11.7% and accounts for
      approximately 1.2 million migraine visits to US emergency departments per year . There are
      numerous studies that discuss treatment for migraine and other benign headaches within the
      emergency department (ED), however, there are very few that discuss specifically the use of
      intravenous fluids (IVF) for headache treatment. Many of these studies look at various
      options for treating migraine and other benign headaches: treatment options include dopamine
      antagonists, opioids, non-steroid anti-inflammatory drugs (NSAIDs), triptans, anti-epileptics
      and ergot derivatives. Comparisons have been done between many of these treatment options
      with dopamine antagonists appearing to be the most effective, compared to other treatments
      The dopamine antagonist with the most evidence and availability for benign headaches is
      prochlorperazine. Given that IVF administration is a common part of treatment regimen for
      benign headache patients in the emergency department and given the lack of randomized trials
      in adults, the investigators aim to study the use of IVF on pain reduction in headache
      patients in the adult ED. There has been one randomized trial in pediatrics that shows IVF
      may help in patients with migraines, whereas the adult literature has no randomized control
      trials and a review of data shows that fluids do not help relieve pain in migraine headache
      patients. This study will include both adult and pediatric patients presenting to the
      Emergency Department with complaint of benign headache.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single center, prospective, single blinded randomized controlled trial on a
      convenience sample of patients presenting to the adult or pediatric ED with a chief complaint
      of headache. Subjects will only be enrolled when a physician or research assistant who is
      familiar with the study protocol is available to enroll patients. Written, informed consent
      will be obtained from each patient. Consent will include a discussion of the risks and
      benefits. In addition to parental informed consent in the pediatric population, age
      appropriate verbal assent will be obtained from pediatric subjects. After 30 minutes, the
      treating provider will be permitted to administer a &quot;rescue medication&quot; of their choice for
      further treatment. If there is an untoward event that requires the patient to know which IVF
      dose was administered, patient will unblinded and will not continue in the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a single center, prospective, single blinded randomized controlled trial on a convenience sample of patients presenting to the adult or pediatric ED with a chief complaint of headache.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>By necessity the subject will be blinded but the RN administering the IV fluids will need to know the rate of infusion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>60 minutes</time_frame>
    <description>The primary outcome measure will be the difference in pain scores between the 5 cc over an hour and 20 mg/kg (up to 1000 cc) over an hour groups measured as the absolute difference between the means at 60 min.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decline rate of pain</measure>
    <time_frame>60 minutes</time_frame>
    <description>The difference between the rates of decline in pain scores will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admissions</measure>
    <time_frame>60 minutes</time_frame>
    <description>The difference between the rates of admission will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>60 minutes</time_frame>
    <description>The difference between the rates of decline of nausea scores will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>60 minutes</time_frame>
    <description>The difference between the rates of decline of vomiting scores will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication</measure>
    <time_frame>30 minutes</time_frame>
    <description>The difference between the rates of decline of use of rescue medications for headache will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Resolution</measure>
    <time_frame>24-48 hours after discharge.</time_frame>
    <description>The difference between the rates of headache resolution with telephone follow up will be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Treatment Arm will receive: normal saline at 5 ml IV given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study arm patients will receive: normal saline at 20 mL/kg (up to 1000 mL) given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 5mL</intervention_name>
    <description>Control arm subjects will receive Normal Saline 5 mL IV over 1 hour</description>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <other_name>NS</other_name>
    <other_name>Sailine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 20mL/kg</intervention_name>
    <description>Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>NS</other_name>
    <other_name>Sailine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prochlorperazine 0.15 mg/kg up to 10 mg IV</intervention_name>
    <description>Standard Treatment Arm and Study Arm will recieve prochlorperazine 0.15 mg/kg up to 10mg IV slow push</description>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Compazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine 1 mg/kg up to 50 mg IV</intervention_name>
    <description>Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push</description>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 10 to 65 years

          2. Temperature less than 100.4 F

          3. Normal neurologic exam and normal mental status

        Exclusion Criteria:

          1. Pregnant

          2. Meningeal signs are present

          3. Acute angle closure glaucoma is suspected

          4. Head trauma within the previous two weeks

          5. Lumbar puncture within the previous two weeks

          6. Thunderclap onset of the headache

          7. Known allergy to one of the study drugs

          8. History of intracranial hypertension

          9. Is a prisoner

         10. Patient declined informed consent

         11. Non-English speaking patient or parent/guardian for pediatric patients

         12. Attending provider excludes patient

         13. Severe Dehydration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Zitek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center of Southern Nevada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wesley J Forred, RN</last_name>
    <phone>702-224-7124</phone>
    <email>wesley.forred@umcsn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tony Zitek, MD</last_name>
    <phone>813-728-4971</phone>
    <email>zitek10@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yili Gan, MS</last_name>
      <phone>702-383-7336</phone>
      <email>yili.gan@umcsn.com</email>
    </contact>
    <contact_backup>
      <last_name>Ronald Roemer, BS</last_name>
      <phone>702-207-8345</phone>
      <email>ronald.roemer@umcsn.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ami P Shah, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tiffany Waker-Segal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gentges J, Arthur A, Stamile T, Figureido M. Peripheral Intravenous Line Placement and Utilization in an Academic Emergency Department. J Emerg Med. 2016 Feb;50(2):235-8. doi: 10.1016/j.jemermed.2015.08.006.</citation>
    <PMID>26433429</PMID>
  </reference>
  <results_reference>
    <citation>Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9.</citation>
    <PMID>17261680</PMID>
  </results_reference>
  <results_reference>
    <citation>Friedman BW, West J, Vinson DR, Minen MT, Restivo A, Gallagher EJ. Current management of migraine in US emergency departments: an analysis of the National Hospital Ambulatory Medical Care Survey. Cephalalgia. 2015 Apr;35(4):301-9. doi: 10.1177/0333102414539055. Epub 2014 Jun 19.</citation>
    <PMID>24948146</PMID>
  </results_reference>
  <results_reference>
    <citation>Balbin JE, Nerenberg R, Baratloo A, Friedman BW. Intravenous fluids for migraine: a post hoc analysis of clinical trial data. Am J Emerg Med. 2016 Apr;34(4):713-6. doi: 10.1016/j.ajem.2015.12.080. Epub 2015 Dec 30.</citation>
    <PMID>26825817</PMID>
  </results_reference>
  <results_reference>
    <citation>Cicek M, Karcioglu O, Parlak I, Ozturk V, Duman O, Serinken M, Guryay M. Prospective, randomised, double blind, controlled comparison of metoclopramide and pethidine in the emergency treatment of acute primary vascular and tension type headache episodes. Emerg Med J. 2004 May;21(3):323-6.</citation>
    <PMID>15107371</PMID>
  </results_reference>
  <results_reference>
    <citation>Friedman BW, Adewunmi V, Campbell C, Solorzano C, Esses D, Bijur PE, Gallagher EJ. A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches. Ann Emerg Med. 2013 Oct;62(4):311-318.e4. doi: 10.1016/j.annemergmed.2013.03.017. Epub 2013 Apr 6.</citation>
    <PMID>23567060</PMID>
  </results_reference>
  <results_reference>
    <citation>Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010 Jul;56(1):1-6. doi: 10.1016/j.annemergmed.2009.11.020. Epub 2010 Jan 4.</citation>
    <PMID>20045576</PMID>
  </results_reference>
  <results_reference>
    <citation>Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003 Jun;41(6):847-53.</citation>
    <PMID>12764341</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA. 1989 Feb 24;261(8):1174-6.</citation>
    <PMID>2915441</PMID>
  </results_reference>
  <results_reference>
    <citation>Friedman BW, Esses D, Solorzano C, Dua N, Greenwald P, Radulescu R, Chang E, Hochberg M, Campbell C, Aghera A, Valentin T, Paternoster J, Bijur P, Lipton RB, Gallagher EJ. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008 Oct;52(4):399-406. Epub 2007 Nov 19.</citation>
    <PMID>18006188</PMID>
  </results_reference>
  <results_reference>
    <citation>Callan JE, Kostic MA, Bachrach EA, Rieg TS. Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial. J Emerg Med. 2008 Oct;35(3):247-53. doi: 10.1016/j.jemermed.2007.09.047. Epub 2008 Jun 5.</citation>
    <PMID>18534808</PMID>
  </results_reference>
  <results_reference>
    <citation>Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995 Nov;26(5):541-6.</citation>
    <PMID>7486359</PMID>
  </results_reference>
  <results_reference>
    <citation>Miner JR, Fish SJ, Smith SW, Biros MH. Droperidol vs. prochlorperazine for benign headaches in the emergency department. Acad Emerg Med. 2001 Sep;8(9):873-9.</citation>
    <PMID>11535479</PMID>
  </results_reference>
  <results_reference>
    <citation>Dychter SS, Gold DA, Carson D, Haller M. Intravenous therapy: a review of complications and economic considerations of peripheral access. J Infus Nurs. 2012 Mar-Apr;35(2):84-91. doi: 10.1097/NAN.0b013e31824237ce. Review.</citation>
    <PMID>22382792</PMID>
  </results_reference>
  <results_reference>
    <citation>Homer LD, Holmes KR. Risks associated with 72- and 96-hour peripheral intravenous catheter dwell times. J Intraven Nurs. 1998 Sep-Oct;21(5):301-5.</citation>
    <PMID>9814284</PMID>
  </results_reference>
  <results_reference>
    <citation>Myburgh JA. Fluid resuscitation in acute medicine: what is the current situation? J Intern Med. 2015 Jan;277(1):58-68. doi: 10.1111/joim.12326. Epub 2014 Nov 25. Review.</citation>
    <PMID>25352314</PMID>
  </results_reference>
  <results_reference>
    <citation>Tfelt-Hansen P, Pascual J, Ramadan N, Dahl√∂f C, D'Amico D, Diener HC, Hansen JM, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012 Jan;32(1):6-38.</citation>
    <PMID>22384463</PMID>
  </results_reference>
  <results_reference>
    <citation>Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160.</citation>
    <PMID>14979299</PMID>
  </results_reference>
  <results_reference>
    <citation>Patniyot IR, Gelfand AA. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache. 2016 Jan;56(1):49-70. doi: 10.1111/head.12746. Review.</citation>
    <PMID>26790849</PMID>
  </results_reference>
  <results_reference>
    <citation>Richer L, Craig W, Rowe B. Randomized controlled trial of treatment expectation and intravenous fluid in pediatric migraine. Headache. 2014 Oct;54(9):1496-505. doi: 10.1111/head.12443. Epub 2014 Aug 28.</citation>
    <PMID>25168404</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center of Southern Nevada</investigator_affiliation>
    <investigator_full_name>Joseph Anthony Zitek</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Headache</keyword>
  <keyword>Benign Headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

